Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loxenatide for Islet Alpha Cell Function in Newly Diagnosed T2DM
NCT06825182Phase 3Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Nov 2024
- Primary completion
- Aug 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of loxenatide in type 2 diabetes mellitus (T2DM), sponsored by Nanjing First Hospital. Primary endpoint: Glucagon levels at 3 months. Started Nov 2024; status: recruiting.
02
Drugs
loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06825182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825182.